Paracetamol hepatotoxicity in metallothionein-null mice

Area of Science:

• Biochemistry
• Toxicology
• Genetics

Background:

• Metallothionein (MT) is a crucial protein involved in cellular defense mechanisms.
• Paracetamol (PCT) overdose is a leading cause of acute liver failure.
• Understanding MT's protective role against PCT toxicity is vital for developing therapeutic strategies.

Purpose of the Study:

• To investigate the role of metallothionein (MT) in protecting the liver against paracetamol (PCT) toxicity.
• To compare PCT-induced hepatotoxicity in mice lacking MT expression (MT -/-) versus wild-type mice (MT +/+).
• To evaluate the influence of feeding status and glycogen levels on MT's protective effects.

Main Methods:

• In vivo studies using MT -/- and MT +/+ mice under fed and fasted conditions.
• Administration of varying doses of paracetamol (PCT) and assessment of hepatotoxicity markers (LDH, ALT).
• In vitro studies using cultured hepatocytes to examine PCT toxicity and the effects of dexamethasone (Dex) and zinc (Zn).

Main Results:

• MT -/- mice exhibited significantly greater hepatotoxicity following PCT administration in the fed state compared to MT +/+ mice.
• Fasting reduced hepatotoxicity in both genotypes, diminishing the observed difference between MT -/- and MT +/+ mice.
• Hepatocytes treated with dexamethasone showed protection against PCT toxicity, suggesting MT's role in mitigating damage.

Conclusions:

• Metallothionein (MT) plays a significant protective role against paracetamol (PCT)-induced liver toxicity, particularly in the fed state.
• The protective effect of MT is diminished when hepatic glycogen stores are depleted due to fasting.
• These findings highlight MT as a potential therapeutic target for managing paracetamol poisoning.